Ofatumumab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade from ProteoGenix; catalogue PX-TA1146; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Ofatumumab Biosimilar is a monoclonal antibody (mAb) that targets the protein CD20 on the surface of B-cells. It is a biosimilar of the original drug, Ofatumumab, and has been developed for research purposes. In this article, we will discuss the structure, activity, and potential applications of this biosimilar in the field of medicine.
Ofatumumab Biosimilar is a fully humanized IgG1 kappa monoclonal antibody. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab regions are responsible for binding to the CD20 protein, while the Fc region plays a role in immune effector functions.
The primary activity of Ofatumumab Biosimilar is to target and bind to the CD20 protein on the surface of B-cells. This binding leads to the depletion of B-cells through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. By depleting B-cells, Ofatumumab Biosimilar can modulate the immune response and potentially treat various diseases.
CD20 is a transmembrane protein expressed on the surface of B-cells, including both normal and malignant B-cells. It plays a crucial role in the development and differentiation of B-cells. However, in certain diseases, such as B-cell lymphomas and autoimmune disorders, CD20 becomes overexpressed, leading to abnormal B-cell proliferation. Ofatumumab Biosimilar specifically targets CD20, leading to the depletion of these abnormal B-cells and potentially treating these diseases.
In addition to targeting CD20, Ofatumumab Biosimilar can also activate immune effector functions through its Fc region. The Fc region can bind to Fc receptors on the surface of immune cells, such as natural killer (NK) cells and macrophages, triggering ADCC and CDC. This results in the destruction of B-cells and further modulates the immune response.
Ofatumumab Biosimilar has potential applications in the field of medicine, particularly in the treatment of B-cell-related disorders. Some of the diseases that could potentially benefit from this biosimilar include:
B-cell Lymphomas B-cell lymphomas are a group of cancers that originate from abnormal B-cells. Ofatumumab Biosimilar can target and deplete these abnormal B-cells, potentially treating B-cell lymphomas. It has shown promising results in clinical trials for the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma.
Autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, are characterized by an overactive immune response. Ofatumumab Biosimilar can modulate the immune response by depleting B-cells, potentially treating these disorders. It has shown efficacy in clinical trials for the treatment of rheumatoid arthritis and multiple sclerosis.
transplant rejection occurs when the immune system recognizes the transplanted organ as foreign and attacks it. B-cells play a role in this process by producing antibodies against the transplanted organ. Ofatumumab Biosimilar can deplete these B-cells and potentially prevent organ transplant rejection.
In addition to the above applications, Ofatumumab Biosimilar is also being studied for its potential in treating other diseases, such as autoimmune hemolytic anemia and pemphigus vulgaris. It may also have a role in combination therapy with other drugs for the treatment of certain cancers.
ProteoGenix catalogue number PX-TA1146. For research use only.
Target: Ofatumumab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Molecular weight: 149kDa; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Ofatumumab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
